Sorscher Steven M, Greco Frank Anthony
Oncology Section, Department of Medicine, Washington University, St. Louis, Mo., and USA.
Case Rep Oncol. 2012 May;5(2):229-32. doi: 10.1159/000339130. Epub 2012 May 10.
Cancer of unknown primary (CUP) is a clinical syndrome representing many types of cancers and diagnoses are typically made after review of clinical presentation, pathology (including immunohistochemical staining) and imaging studies. Treatment with systemic chemotherapy has been shown to result in fairly reproducible objective response rates. Herein, a case of a patient who was initially diagnosed with a poorly differentiated adenocarcinoma of unknown origin is reported. After mRNA gene expression profiling (commercially available CancerTYPE ID), a specific diagnosis of papillary renal cell carcinoma (RCC) was made and then confirmed with additional immunohistochemical staining. The patient was treated with targeted therapy and an objective radiographic response was seen. A literature review suggests this to be the first patient with papillary RCC, identified by molecular profiling, and benefitting from a targeted agent that otherwise would not have been considered in the setting of CUP. This case underscores the importance of considering the use of newer testing technologies in the interest of offering patients more specific, targeted therapy in order to improve efficacy and spare patients toxicities of less specific, empiric chemotherapeutic regimens.
原发灶不明的癌症(CUP)是一种临床综合征,涵盖多种类型的癌症,其诊断通常在对临床表现、病理(包括免疫组化染色)和影像学检查进行评估后作出。全身化疗已显示能产生相当可重复的客观缓解率。在此,报告一例最初被诊断为来源不明的低分化腺癌的患者。经mRNA基因表达谱分析(市售的CancerTYPE ID)后,作出了乳头状肾细胞癌(RCC)的明确诊断,随后通过额外的免疫组化染色得以证实。该患者接受了靶向治疗,并出现了客观的影像学缓解。文献综述表明,这是首例通过分子谱分析确诊为乳头状RCC并受益于靶向药物的患者,否则在CUP的情况下不会考虑使用该药物。该病例强调了考虑使用更新的检测技术的重要性,以便为患者提供更具特异性的靶向治疗,从而提高疗效并避免患者遭受非特异性经验性化疗方案的毒性。